{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:53:06Z","timestamp":1788850386111,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06659-6","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T02:53:09Z","timestamp":1762743189000},"page":"5593-5603","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Optimizing the use of melflufen (melphalan flufenamide) in relapsed or refractory multiple myeloma: recommendations for clinical practice"],"prefix":"10.1007","volume":"104","author":[{"given":"Heinz","family":"Ludwig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias K.","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"H\u00f6gner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Welslau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes M.","family":"Waldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"6659_CR1","unstructured":"SmPC (2025) https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/pepaxti-epar-production-information_en.pdf"},{"key":"6659_CR2","unstructured":"FDA. FDA issues final decision to withdraw approval of Pepaxto (melphalan flufenamide) (2025) US Food & Drug Administration website [23-Feb-2024]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-issues-final-decision-withdraw-approval-pepaxto-melphalan-flufenamide"},{"issue":"10","key":"6659_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103120","volume":"9","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Blade J, Bringhen S (2020) Melflufen: a peptide-drug conjugate for the treatment of multiple myeloma. J Clin Med 9(10):3120. https:\/\/doi.org\/10.3390\/jcm9103120","journal-title":"J Clin Med"},{"issue":"39","key":"6659_CR4","doi-asserted-by":"publisher","first-page":"66641","DOI":"10.18632\/oncotarget.18420","volume":"8","author":"M Wickstrom","year":"2017","unstructured":"Wickstrom M, Nygren P, Larsson R et al (2017) Melflufen - a peptidase-potentiated alkylating agent in clinical trials. Oncotarget 8(39):66641\u201366655. https:\/\/doi.org\/10.18632\/oncotarget.18420","journal-title":"Oncotarget"},{"issue":"6","key":"6659_CR5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/10611860310001647140","volume":"11","author":"J Gullbo","year":"2003","unstructured":"Gullbo J, Wickstrom M, Tullberg M et al (2003) Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1. J Drug Target 11(6):355\u2013363. https:\/\/doi.org\/10.1080\/10611860310001647140","journal-title":"J Drug Target"},{"issue":"3","key":"6659_CR6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/j.1349-7006.2010.01826.x","volume":"102","author":"M Wickstrom","year":"2011","unstructured":"Wickstrom M, Larsson R, Nygren P et al (2011) Aminopeptidase N (CD13) as a target for cancer chemotherapy. Cancer Sci 102(3):501\u2013508. https:\/\/doi.org\/10.1111\/j.1349-7006.2010.01826.x","journal-title":"Cancer Sci"},{"issue":"9","key":"6659_CR7","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.bcp.2009.12.022","volume":"79","author":"M Wickstrom","year":"2010","unstructured":"Wickstrom M, Viktorsson K, Lundholm L et al (2010) The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of Melphalan. Biochem Pharmacol 79(9):1281\u20131290. https:\/\/doi.org\/10.1016\/j.bcp.2009.12.022","journal-title":"Biochem Pharmacol"},{"key":"6659_CR8","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.bbrc.2023.03.009","volume":"656","author":"U Westermark","year":"2023","unstructured":"Westermark U, Diao Y, Fasth KJ (2023) A rapid intracellular enrichment of alkylating payload is essential for Melphalan flufenamide potency and mechanism of action. Biochem Biophys Res Commun 656:122\u2013130. https:\/\/doi.org\/10.1016\/j.bbrc.2023.03.009","journal-title":"Biochem Biophys Res Commun"},{"key":"6659_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071527","author":"JJ Miettinen","year":"2021","unstructured":"Miettinen JJ, Kumari R, Traustadottir GA (2021) Aminopeptidase expression in multiple myeloma associates with disease progression and sensitivity to Melflufen. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13071527","journal-title":"Cancers (Basel)"},{"issue":"11","key":"6659_CR10","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1158\/1078-0432.CCR-12-3752","volume":"19","author":"D Chauhan","year":"2013","unstructured":"Chauhan D, Ray A, Viktorsson K et al (2013) In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Clin Cancer Res 19(11):3019\u20133031. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3752","journal-title":"Clin Cancer Res"},{"issue":"3","key":"6659_CR11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/bjh.14065","volume":"174","author":"A Ray","year":"2016","unstructured":"Ray A, Ravillah D, Das DS (2016) A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells. Br J Haematol 174(3):397\u2013409. https:\/\/doi.org\/10.1111\/bjh.14065","journal-title":"Br J Haematol"},{"key":"6659_CR12","doi-asserted-by":"crossref","unstructured":"Acs K, Miettinen JJ, Sergeev P et al (2024) Efficacy of Melflufen in patients with Relapsed\/Refractory multiple myeloma and mutated or deleted TP53. medRxiv","DOI":"10.1101\/2024.12.02.24318289"},{"issue":"5","key":"6659_CR13","doi-asserted-by":"publisher","first-page":"e395","DOI":"10.1016\/S2352-3026(20)30044-2","volume":"7","author":"PG Richardson","year":"2020","unstructured":"Richardson PG, Bringhen S, Voorhees P et al (2020) Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1\u20132 study. Lancet Haematol 7(5):e395\u2013e407. https:\/\/doi.org\/10.1016\/S2352-3026(20)30044-2","journal-title":"Lancet Haematol"},{"issue":"7","key":"6659_CR14","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1200\/JCO.20.02259","volume":"39","author":"PG Richardson","year":"2021","unstructured":"Richardson PG, Oriol A, Larocca A (2021) Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma. J Clin Oncol 39(7):757\u2013767. https:\/\/doi.org\/10.1200\/JCO.20.02259","journal-title":"J Clin Oncol"},{"issue":"2","key":"6659_CR15","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1016\/S2352-3026(21)00381-1","volume":"9","author":"FH Schjesvold","year":"2022","unstructured":"Schjesvold FH, Dimopoulos MA, Delimpasi S et al (2022) Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Lancet Haematol 9(2):e98\u2013e110. https:\/\/doi.org\/10.1016\/S2352-3026(21)00381-1","journal-title":"Lancet Haematol"},{"issue":"1","key":"6659_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1182\/blood-2020-137118","volume":"136","author":"P Richardson","year":"2020","unstructured":"Richardson P, Mateos MV, Oriol A (2020) HORIZON (OP-106): Melflufen plus dexamethasone (dex) in 55 patients (pts) with Relapsed\/Refractory multiple myeloma (RRMM) with extramedullary disease (EMD)-Subgroup analysis. Blood 136(1):15\u201317. https:\/\/doi.org\/10.1182\/blood-2020-137118","journal-title":"Blood"},{"issue":"Suppl 1","key":"6659_CR17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-177945","volume":"142","author":"F Schjesvold","year":"2023","unstructured":"Schjesvold F, Dimopoulos MA, Delimpasi S et al (2023) Long-term outcomes from the phase 3 OCEAN (OP-103) study: melflufen and dexamethasone (Dex) versus pomalidomide (Pom) and Dex in relapsed refractory multiple myeloma (RRMM). Blood 142(Suppl 1):2018. https:\/\/doi.org\/10.1182\/blood-2023-177945","journal-title":"Blood"},{"key":"6659_CR18","unstructured":"EPAR (2022) https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/pepaxti-epar-public-assessment-report_en.pdf"},{"issue":"9","key":"6659_CR19","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.clml.2023.05.004","volume":"23","author":"P Sonneveld","year":"2023","unstructured":"Sonneveld P, Richardson PG, Ludwig H et al (2023) Benefit versus risk assessment of Melflufen and dexamethasone in relapsed\/refractory multiple myeloma: analyses from longer follow-up of the OCEAN and HORIZON studies. Clin Lymphoma Myeloma Leuk 23(9):687\u2013696. https:\/\/doi.org\/10.1016\/j.clml.2023.05.004","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6659_CR20","unstructured":"Data-on-file (2025) ALL-DOF-000055: PFS for target population in OCEAN. Oncopeptides"},{"key":"6659_CR21","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283490","author":"EM Ocio","year":"2023","unstructured":"Ocio EM, Efebera YA, Hajek R (2023) Anchor: Melflufen plus dexamethasone and daratumumab or bortezomib in relapsed\/refractory multiple myeloma-final results of a phase I\/IIa study. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2023.283490","journal-title":"Haematologica"},{"issue":"3","key":"6659_CR22","doi-asserted-by":"publisher","first-page":"895","DOI":"10.3324\/haematol.2023.283509","volume":"109","author":"L Pour","year":"2023","unstructured":"Pour L, Szarejko M, Bila J (2023) Efficacy and safety of Melflufen plus daratumumab and dexamethasone in relapsed\/refractory multiple myeloma: results from the randomized, open-label, phase III lighthouse study. Haematologica 109(3):895\u2013905. https:\/\/doi.org\/10.3324\/haematol.2023.283509","journal-title":"Haematologica"},{"key":"6659_CR23","unstructured":"Schjesvold F, Dimopoulos M, Pour L et al (2024) The effect of transplant status on exposure-adjusted AE rates in melflufen-treated RRMM patients in a pooled safety population from 4 studies. Controversies in Multiple Myeloma (COMy) 23\u201326 May 2024.https:\/\/comylive.cme-congreshses.com\/wp-content\/uploads\/2024\/05\/37.pdf"},{"issue":"6","key":"6659_CR24","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1016\/j.clml.2024.02.012","volume":"24","author":"L Pour","year":"2024","unstructured":"Pour L, Micheva I, Usenko G et al (2024) PORT: a randomized, cross-over, phase 2 study of Melflufen peripheral versus central intravenous administration in patients with relapsed\/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 24(6):e267-e275e2. https:\/\/doi.org\/10.1016\/j.clml.2024.02.012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"6659_CR25","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1182\/blood.2020005125","volume":"136","author":"CA Bradbury","year":"2020","unstructured":"Bradbury CA, Craig Z, Cook G et al (2020) Thrombosis in patients with myeloma treated in the myeloma IX and myeloma XI phase 3 randomized controlled trials. Blood 136(9):1091\u20131104. https:\/\/doi.org\/10.1182\/blood.2020005125","journal-title":"Blood"},{"issue":"3","key":"6659_CR26","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","volume":"5","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E et al (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5(3):632\u2013634. https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02374.x","journal-title":"J Thromb Haemost"},{"issue":"11","key":"6659_CR27","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.3324\/haematol.2022.280893","volume":"107","author":"V De Stefano","year":"2022","unstructured":"De Stefano V, Larocca A, Carpenedo M et al (2022) Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel. Haematologica 107(11):2536\u20132547. https:\/\/doi.org\/10.3324\/haematol.2022.280893","journal-title":"Haematologica"},{"issue":"1","key":"6659_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","volume":"11","author":"SV Rajkumar","year":"2010","unstructured":"Rajkumar SV, Jacobus S, Callander NS et al (2010) Lenalidomide plus high-dose dexamethasone versus Lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11(1):29\u201337. https:\/\/doi.org\/10.1016\/S1470-2045(09)70284-0","journal-title":"Lancet Oncol"},{"key":"6659_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100757","volume":"46","author":"C Poh","year":"2021","unstructured":"Poh C, Keegan T, Rosenberg AS (2021) Second primary malignancies in multiple myeloma: a review. Blood Rev 46:100757. https:\/\/doi.org\/10.1016\/j.blre.2020.100757","journal-title":"Blood Rev"},{"issue":"12","key":"6659_CR30","doi-asserted-by":"publisher","first-page":"e906","DOI":"10.1016\/S2352-3026(22)00289-7","volume":"9","author":"K Saleem","year":"2022","unstructured":"Saleem K, Franz J, Klem ML (2022) Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis. Lancet Haematol 9(12):e906\u2013e918. https:\/\/doi.org\/10.1016\/S2352-3026(22)00289-7","journal-title":"Lancet Haematol"},{"issue":"11","key":"6659_CR31","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1080\/14740338.2023.2274420","volume":"22","author":"S Midha","year":"2023","unstructured":"Midha S, Hartley-Brown MA, Mo CC et al (2023) A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma. Expert Opin Drug Saf 22(11):1049\u20131071. https:\/\/doi.org\/10.1080\/14740338.2023.2274420","journal-title":"Expert Opin Drug Saf"},{"key":"6659_CR32","doi-asserted-by":"publisher","unstructured":"Robak T, Delimpasi S, Pour L et al (2021) OCEAN (OP-103): Melflufen plus dexamethasone (Dex) versus Pomalidomide (Pom) and Dex in relapsed refractory multiple myeloma (RRMM) - Renal impairment (RI) analysis [Congress abstract]. Blood 138:Suppl 1. https:\/\/doi.org\/10.1182\/blood-2021-146550.\u00a0","DOI":"10.1182\/blood-2021-146550"},{"issue":"3","key":"6659_CR33","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/bjh.17887","volume":"196","author":"A Larocca","year":"2022","unstructured":"Larocca A, Leleu X, Touzeau C et al (2022) Patient-reported outcomes in relapsed\/refractory multiple myeloma treated with Melflufen plus dexamethasone: analyses from the phase II HORIZON study. Br J Haematol 196(3):639\u2013648. https:\/\/doi.org\/10.1111\/bjh.17887","journal-title":"Br J Haematol"},{"issue":"7","key":"6659_CR34","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.3324\/haematol.2023.284635","volume":"109","author":"FH Schjesvold","year":"2024","unstructured":"Schjesvold FH, Ludwig H, Delimpasi S et al (2024) Health-related quality of life in relapsed\/refractory multiple myeloma treated with Melflufen and dexamethasone: analyses from the phase III OCEAN study. Haematologica 109(7):2331\u20132336. https:\/\/doi.org\/10.3324\/haematol.2023.284635","journal-title":"Haematologica"},{"key":"6659_CR35","unstructured":"Data-on-file (2025) ALL-DOF-000070: ASCT by age group. Oncopeptides"},{"issue":"3","key":"6659_CR36","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/ejh.14127","volume":"112","author":"FH Schjesvold","year":"2024","unstructured":"Schjesvold FH, Ludwig H, Mateos MV et al (2024) Melflufen in relapsed\/refractory multiple myeloma refractory to prior alkylators: a subgroup analysis from the OCEAN study. Eur J Haematol 112(3):402\u2013411. https:\/\/doi.org\/10.1111\/ejh.14127","journal-title":"Eur J Haematol"},{"issue":"9","key":"6659_CR37","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","volume":"22","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M et al (2025) EHA\u2013EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol 22(9):680\u2013700. https:\/\/doi.org\/10.1038\/s41571-025-01041-x","journal-title":"Nat Rev Clin Oncol"},{"key":"6659_CR38","unstructured":"Pour L, Delimpasi S, Legiec W et al (2021) BRIDGE (OP-107): A phase 2 Pharmacokinetic study of Melflufen plus dexamethasone in patients with relapsed\/refractory multiple myeloma and impaired renal function. European Hematology Association (EHA). Virtual."},{"key":"6659_CR39","unstructured":"Waldschmidt J, B\u00f6ck H-P, Basovski L et al (2024) HARBOUR (OP-113): A non-interventional study of Melphalan flufenamide (melflufen) in combination with dexamethasone in patients with relapsed and\/or refractory multiple myeloma (RRMM) according to the approved label. Oncol Res Treat 47:Suppl 2:285."},{"key":"6659_CR40","unstructured":"REEC. Registro Espa\u00f1ol de Estudios Cl\u00ednicos (2025) Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios Available from: https:\/\/reec.aemps.es\/reec\/public\/eo_detail.html"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06659-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06659-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06659-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T02:31:34Z","timestamp":1764729094000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06659-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":40,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["6659"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06659-6","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H.L: Research Support: Sanofi, Amgen. Speakers Bureau\/Advisory Boards: Janssen, Sanofi, Pfizer, GSK, Pfizer, OncopeptidesE.K.M: Advisory Board: Amgen, Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen-Cilag, Menarini Stemline, Oncopeptides, Sanofi und Takeda. Honoraria: Amgen, Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen-Cilag, Menarini Stemline, Oncopeptides, Sanofi und Takeda. Research Funding: Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi und Takeda. Travel expanses: Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen-Cilag, Menarini Stemline, Pfizer, Sanofi und TakedaM.H. received payments for Advisory boards or travel grants from Jansen Cilag, Sanofi Aventis, Oncopeptides, Takeda Oncology, Pfizer OncologyM.W.: Advisory board: Amgen, Bristol-Myers Squibb, Celgene, Gilead, Hexal, Janssen, Lilly, Medac, Novartis, Roche, Sanofi, Astra Zeneca, Oncopeptids. Honoraria: Amgen, Astellas, AstraZeneca, Celgene, Gilead, Hexal, Janssen, Lilly, Novartis, Roche, Sanofi, Daichii-Sankyo, OncopeptidsJ.M.W. has consulted for Johnson&Johnson, BMS, Sanofi, Take\u00acda, Pfizer, Oncopeptides and Skyline Dx; received honoraria from Takeda, GSK, Pharmamar and Beigene; and received research support from BMS.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}